Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 211

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 211
---
 6,647,715

    Total liabilities and stockholders’ equity
     
    $
    6,622,049

    $
    12,212,609

See accompanying notes to the consolidated financial statements.

 F-4

REVELATION BIOSCIENCES, INC.

Consolidated Statements of Operations

    Year EndedDecember 31,

    2024

    2023

    Operating expenses:

    Research and development
     
    $
    3,548,996

    $
    4,145,902

    General and administrative

    4,426,113

    4,510,762

    Total operating expenses

    7,975,109

    8,656,664

    Loss from operations

    (7,975,109
    )

    (8,656,664
    )

    Other (expense) income:

    Change in fair value of warrant liability

    81,441

    8,328,937

    Other (expense) income, net

    (7,144,868
    )

    207,473

    Total other (expense) income, net

    (7,063,427
    )

    8,536,410

    Net loss
     
    $
    (15,038,536
    )
     
    $
    (120,254
    )

    Net loss per share, basic and diluted
     
    $
    (87.68
    )
     
    $
    (8.44
    )

    Weighted-average shares used to compute net loss per share, basic and diluted

    171,510

    14,246

See accompanying notes to the consolidated financial statements.

 F-5

REVELATION BIOSCIENCES, INC. 

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

    Series A Preferred Stock

    Common Stock

    Additional Paid-in

    Accumulated

    Total Stockholders’

    Shares

    Amount

    Shares

    Amount

    Capital

    Deficit

    Equity

    Balance as of December 31, 2022 (as previously reported)

    1

    $
    —

    77,375

    $
    77

    $
    26,399,224

    $
    (25,346,848
    )
     
    $
    1,052,